The Pharmacy Times® Gastrointestinal Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that occur in digestive tract organs, such as the stomach, large and small intestine, pancreas, colon, liver, rectum, anus, and biliary system.
April 29th 2024
Trastuzumab is indicated for adjuvant breast cancer, metastatic breast cancer, and gastric cancer.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Three Major Studies Alter the Practice of Treating Gastroesophageal Carcinomas
April 12th 2021A presentation at the Community Oncology Alliance 2021 Virtual Conference focused on the latest developments in gastrointestinal oncology and how the field of gastroesophageal cancer is responding to 3 major, practice-changing trials.
Read More
Plethora of Clinical Trials Explore Gastric Cancer Treatments
Pharmacists can play an integral role in collaborating with physicians to manage patient therapy.
Read More
FDA Gives Fast Track Designation for Gastric, Gastroesophageal Junction Adenocarcinoma Treatment
September 25th 2020The FDA has granted fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression.
Read More
FDA Approves New Treatment for Gastric, Gastroesophageal Junction Adenocarcinoma
February 26th 2019The FDA approved trifluridine/tipiracil (Lonsurf, Taiho Oncology), also known as TAS-102, as a treatment for certain adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More
FDA Approves TAS-102 for Treating Adults With Gastric/GEJ Cancer
February 25th 2019The drug is indicated for those patients who were previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Read More